SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis A case reportSARS-CoV-2(COVID-19) 폐렴 환자, 급성 중증 궤양성 대장염 2주 이내 인플릭시맙 2회 투여 증례 보고Case Reports Published on 2022-01-282022-09-12 Journal: Medicine [Category] 진단, [키워드] abdominal pain acute COVID-19 acute respiratory syndrome Administered an infectious disease caused by the SARS-CoV-2 virus anti-TNF anti-TNF-α azathioprine bleeding bloody can be used Case report caused Clostridium difficile Colitis Colon complications coronavirus Corticosteroid Corticosteroids COVID-19 COVID-19 infection COVID-19 patient COVID-19 symptom COVID-19 symptoms current cytomegalovirus deteriorate diagnosed diagnosis of COVID-19 diarrhea dose Fever Immune-mediated inflammatory diseases Immunosuppressant immunosuppressants Immunotherapy IMPROVE induce Infection Infectious disease Inflammatory diseases infliximab inhibitor intravenous Loading dose male mesalamine Nasopharyngeal swab Necrosis necrosis factor antagonists nine outcomes pandemic Patient Pneumonia positive receiving Remission Research SARS-CoV-2 SARS-CoV-2 virus Severe acute respiratory syndrome Sigmoidoscopy spontaneous bleeding surgery tested the SARS-CoV-2 virus therapy treated Treatment Tumor tumor necrosis tumor necrosis factor ulcerative colitis [DOI] 10.1097/MD.0000000000028722 PMC 바로가기 [Article Type] Case Reports
COVID GEAS: COVID-19 National Survey in Patients With Systemic Autoimmune DiseasesMedicine Published on 2022-01-272022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] age analyzed anti-TNF Autoimmune diseases Autoimmunity clinical factor Comorbidity Corticosteroids COVID COVID-19 COVID-19 infection cross-sectional survey cumulative incidence Department disease Disease diagnosis Emergency evaluated General population Hospitalization individual Infection medication Mild Multivariate analysis objective outcome Patient positive patients primary care receiving required Result risk SARS-CoV-2 SARS-COV-2 infection Severity of disease Sex significant difference smoking status survey systemic systemic autoimmune disease Systemic autoimmune diseases systemic erythematosus lupus Treatment was performed with COVID-19 [DOI] 10.3389/fmed.2021.808608 PMC 바로가기 [Article Type] Medicine
Humoral Immune Response in IBD Patients Three and Six Months after Vaccination with the SARS-CoV-2 mRNA Vaccines mRNA-1273 and BNT162b2Article Published on 2022-01-132022-10-28 Journal: Biomedicines [Category] COVID-19, [키워드] acute respiratory syndrome anti-TNF approach BNT162b2 booster coronavirus disease COVID-19 COVID-19 mRNA Vaccination domain Efficacy Evidence examined healthy control healthy subjects humoral IBD IBD patients IgG antibody Immunosuppressed Inflammatory bowel disease Month mRNA mRNA-1273 Necrosis neutralization neutralizing capacity not differ pandemic Patient patients patients treated Prospective Study response SARS-CoV-2 second vaccination Seroconversion seroconversion rate significant difference significantly lower spike-protein sVNT the SARS-CoV-2 therapy TNF two group vaccination Vaccine [DOI] 10.3390/biomedicines10010171 PMC 바로가기 [Article Type] Article
Crohn’s and Colitis Canada’s 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines—Biology, Current Evidence and RecommendationsSupplement Articles Published on 2021-12-052022-10-29 Journal: Journal of the Canadian Association of Gastroenterology [Category] COVID-19, [키워드] adverse event anti-TNF approved Canada Chronic diseases Complete COVID-19 COVID-19 infection COVID-19 pandemic Crohn’s disease current death Efficacy Evidence first dose General population groups IBD immune response Immune-mediated Immunosuppressant Impact individual Inflammatory bowel disease International methotrexate National produced receive receiving reducing Regulatory robust SARS-CoV-2 SARS-CoV-2 vaccine SARS-CoV-2 vaccines second dose shown symptomatic the vaccine therapy These data Trial ulcerative colitis vaccination Vaccine Vaccine development Vaccines were excluded [DOI] 10.1093/jcag/gwab033 PMC 바로가기 [Article Type] Supplement Articles
Therapies for inflammatory bowel disease do not pose additional risks for adverse outcomes of SARS-CoV-2 infection: an IG-IBD studyObservational Study Published on 2021-12-012022-10-05 Journal: Alimentary pharmacology & therapeutics [Category] SARS, 임상, [키워드] Active disease adverse outcome adverse outcomes age anti-TNF Asymptomatic build cohort study Comorbidity Course COVID-19 COVID-19 in patient death disease evaluated General population greater help higher risk hospitalisation IBD identify Immune-mediated Inflammatory bowel disease inflammatory disease lower risk medication moderate multivariable analyses multivariable logistic regression obesity outcome outcomes Patient patients Pneumonia risk risk factor Risk factors SARS-CoV-2 SARS-COV-2 infection severe COVID-19 significantly therapy ulcerative colitis ventilatory support was used [DOI] 10.1111/apt.16663 PMC 바로가기 [Article Type] Observational Study
Humoral protection to SARS-CoV2 declines faster in patients on TNF alpha blocking therapiesSARS-CoV2에 대한 체액 보호는 TNF 알파 차단 요법을 받는 환자에서 더 빨리 감소합니다Article Published on 2021-12-012022-09-11 Journal: RMD Open [Category] 변종, 진단, [키워드] Anti-spike anti-Spike IgG anti-TNF Antigen appearance Arthritis blockade booster booster vaccination booster vaccinations CD4+ T cell CD4+ T-cell chronic inflammatory disease chronic inflammatory diseases clinically Cohort controls COVID-19 Critical Decline declined Efficacy faster Frequency greater groups healthy controls healthy individual humoral immune response Humoral response humoral responses IgA level IgA levels IgG immune responses Inflammatory diseases lack mRNA vaccination Necrosis neutralization Neutralizing antibodies no differences pandemic Patient patients persistence receiving regimens response SARS-CoV2 second vaccination significantly T cell therapy TNF TNF alpha Treatment Tumor tumor necrosis tumor necrosis factor tumor necrosis factor inhibitors vaccination vaccine response vaccine responses variants while [DOI] 10.1136/rmdopen-2021-002008 PMC 바로가기 [Article Type] Article
The Impact of Vedolizumab on COVID-19 Outcomes Among Adult IBD Patients in the SECURE-IBD RegistrySECURE-IBD 레지스트리에서 성인 IBD 환자의 COVID-19 결과에 대한 베돌리주맙의 영향Article Published on 2021-11-082022-09-12 Journal: Journal of Crohn's & colitis [Category] MERS, SARS, 진단, [키워드] 95% CI 95% confidence interval adjusted odds ratio anti-TNF appear bowel Care comparable coronavirus disease Coronavirus disease 2019 covariates COVID-19 COVID-19 hospitalization Crohn’s disease determine Exploratory analysis Gastrointestinal symptom Hospitalization IBD Impact Inflammatory bowel disease International mechanical ventilation medication monotherapy multivariable analysis Necrosis outcome outcomes Patient patients patients with COVID-19 registry Safe severe COVID-19 Therapies therapy ulcerative ulcerative colitis vedolizumab [DOI] 10.1093/ecco-jcc/jjab071 PMC 바로가기 [Article Type] Article
Risk of infection associated with Janus Kinase (JAK) inhibitors and biological therapies in inflammatory intestinal disease and rheumatoid arthritis. Prevention strategies염증성 장 질환 및 류마티스 관절염에서 Janus Kinase (JAK) 억제제와 생물학적 치료와 관련된 감염 위험. 예방 전략.Review Published on 2021-10-012023-05-31 Journal: Gastroenterología y hepatología [Category] B형 간염, 대상포진, 두창, 수두, 홍역, [키워드] anti-TNF Artritis reumatoide Biológicos biologics Enfermedad inflamatoria intestinal Immunosuppression Infecciones infections Inflammatory bowel disease Inhibidores del JAK Inmunosupresión jak inhibitors rheumatoid arthritis Tofacitinib Vaccines vacunas [DOI] 10.1016/j.gastrohep.2021.01.007 [Article Type] Review
A Prospective Observational Study on the Efficacy and Safety of Infliximab-Biosimilar (CT-P13) in Patients With Takayasu Arteritis (TAKASIM)Original Research Published on 2021-09-272024-09-02 Journal: Frontiers in Medicine [Category] 대상포진, [키워드] anti-TNF bDMARD biologic drug biosimilar drug infliximab Takayasu arteritis therapy [DOI] 10.3389/fmed.2021.723506 PMC 바로가기 [Article Type] Original Research
TNF-α synergises with IFN-γ to induce caspase-8-JAK1/2-STAT1-dependent death of intestinal epithelial cellsArticle Published on 2021-09-232022-10-04 Journal: Cell Death & Disease [Category] 신약개발, [키워드] Activation anti-TNF Apoptosis autoinflammatory disease biochemical biopsy canonical CASP8 caspase caspase-8 cell death Cell death and immune response contribute Critical Crohn's disease Crohn’s disease cytokine death dependence driven by driver epithelial Ex vivo feature Genetic Gut Host IBD IEC IFN-γ immunopathology independent induce Inflammatory bowel disease inhibitor interferons intestinal epithelial cell Intestinal Organoids involved JAK inhibitor kill killing kinase loss-of-function mechanisms MLKL mucosal necroptosis Organoid pathway required retained sustained synergistic T cells therapeutic efficacy TNF-α TNFR1 Tumour-necrosis factors ZBP1 [DOI] 10.1038/s41419-021-04151-3 PMC 바로가기 [Article Type] Article